NEW YORK, May 21 (Reuters) - Bristol-Myers Squibb Co.'s schizophrenia drug Abilify proved effective as an add-on therapy for patients suffering from major depression who were not getting satisfactory ...
It is an irony that although lithium is not FDA approved as an augmentation strategy for treating depression, there is prob ...
U.S. physicians indicate an almost 50-50 split when asked whether trackable pills will improve patient outcomes, according to a recent survey by SERMO, a global social network for physicians. The ...
NEW YORK, July 17 (Reuters) - Bristol-Myers Squibb Co. and Japan's Otsuka Pharmaceutical Co. said on Tuesday that U.S. health regulators have granted a priority review for their schizophrenia drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results